BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 33902050)

  • 21. Soluble suppression of tumorigenicity 2 (sST2) for predicting disease severity or mortality outcomes in cardiovascular diseases: A systematic review and
    Ip C; Luk KS; Yuen VLC; Chiang L; Chan CK; Ho K; Gong M; Lee TTL; Leung KSK; Roever L; Bazoukis G; Lampropoulos K; Li KHC; Tse G; Liu T;
    Int J Cardiol Heart Vasc; 2021 Dec; 37():100887. PubMed ID: 34712771
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Soluble Suppression of Tumorogenicity 2 Increases Opportunities for Risk Stratification After Acute Heart Failure Decompensation].
    Skvortsov AA; Protasov VN; Narusov OY; Koshkina DE; Nasonova SN; Masenko VP; Tereschenko SN
    Kardiologiia; 2017 Jan; (1):48-58. PubMed ID: 28290833
    [TBL] [Abstract][Full Text] [Related]  

  • 23. sST2 Predicts Outcome in Chronic Heart Failure Beyond NT-proBNP and High-Sensitivity Troponin T.
    Emdin M; Aimo A; Vergaro G; Bayes-Genis A; Lupón J; Latini R; Meessen J; Anand IS; Cohn JN; Gravning J; Gullestad L; Broch K; Ueland T; Nymo SH; Brunner-La Rocca HP; de Boer RA; Gaggin HK; Ripoli A; Passino C; Januzzi JL
    J Am Coll Cardiol; 2018 Nov; 72(19):2309-2320. PubMed ID: 30384887
    [TBL] [Abstract][Full Text] [Related]  

  • 24. sST2 adds to the prognostic value of Gal-3 and BNP in chronic heart failure.
    Barutaut M; Fournier P; Peacock WF; Evaristi MF; Dambrin C; Caubère C; Koukoui F; Galinier M; Smih F; Rouet P
    Acta Cardiol; 2020 Dec; 75(8):739-747. PubMed ID: 31560863
    [No Abstract]   [Full Text] [Related]  

  • 25. Prognostic Value of High-Sensitivity Troponin T in Chronic Heart Failure: An Individual Patient Data Meta-Analysis.
    Aimo A; Januzzi JL; Vergaro G; Ripoli A; Latini R; Masson S; Magnoli M; Anand IS; Cohn JN; Tavazzi L; Tognoni G; Gravning J; Ueland T; Nymo SH; Brunner-La Rocca HP; Bayes-Genis A; Lupón J; de Boer RA; Yoshihisa A; Takeishi Y; Egstrup M; Gustafsson I; Gaggin HK; Eggers KM; Huber K; Tentzeris I; Tang WHW; Grodin J; Passino C; Emdin M
    Circulation; 2018 Jan; 137(3):286-297. PubMed ID: 29335288
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The prognostic value of plasma soluble ST2 in hospitalized Chinese patients with heart failure.
    Zhang R; Zhang Y; Zhang J; An T; Huang Y; Guo X; Januzzi JL; Cappola TP; Yin S; Wang Y; Zhou Q; Zou C; Ji S; Lv R
    PLoS One; 2014; 9(10):e110976. PubMed ID: 25347817
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Increased plasma concentrations of soluble ST2 are predictive for 1-year mortality in patients with acute destabilized heart failure.
    Mueller T; Dieplinger B; Gegenhuber A; Poelz W; Pacher R; Haltmayer M
    Clin Chem; 2008 Apr; 54(4):752-6. PubMed ID: 18375488
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic Value of Baseline and Changes in Circulating Soluble ST2 Levels and the Effects of Nesiritide in Acute Decompensated Heart Failure.
    Tang WH; Wu Y; Grodin JL; Hsu AP; Hernandez AF; Butler J; Metra M; Voors AA; Felker GM; Troughton RW; Mills RM; McMurray JJ; Armstrong PW; O'Connor CM; Starling RC
    JACC Heart Fail; 2016 Jan; 4(1):68-77. PubMed ID: 26656144
    [TBL] [Abstract][Full Text] [Related]  

  • 29. ST2 elevation in heart failure, predictive of a high early mortality.
    Dalal JJ; Digrajkar A; Das B; Bansal M; Toomu A; Maisel AS
    Indian Heart J; 2018; 70(6):822-827. PubMed ID: 30580851
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Role of Soluble ST2 as a Prognostic Marker in Patients with Acute Heart Failure and Renal Insufficiency.
    Kim MS; Jeong TD; Han SB; Min WK; Kim JJ
    J Korean Med Sci; 2015 May; 30(5):569-75. PubMed ID: 25931787
    [TBL] [Abstract][Full Text] [Related]  

  • 31. ST2 may not be a useful predictor for incident cardiovascular events, heart failure and mortality.
    Hughes MF; Appelbaum S; Havulinna AS; Jagodzinski A; Zeller T; Kee F; Blankenberg S; Salomaa V;
    Heart; 2014 Nov; 100(21):1715-21. PubMed ID: 25080471
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Serum aldosterone is associated with mortality and re-hospitalization in patients with reduced ejection fraction hospitalized for acute heart failure: analysis from the EVEREST trial.
    Girerd N; Pang PS; Swedberg K; Fought A; Kwasny MJ; Subacius H; Konstam MA; Maggioni A; Gheorghiade M; Zannad F;
    Eur J Heart Fail; 2013 Nov; 15(11):1228-35. PubMed ID: 23787720
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Serial monitoring of soluble interleukin family member ST2 in patients with acutely decompensated heart failure.
    Manzano-Fernández S; Januzzi JL; Pastor-Pérez FJ; Bonaque-González JC; Boronat-Garcia M; Pascual-Figal DA; Montalban-Larrea S; Navarro-Peñalver M; Andreu-Cayuelas JM; Valdés M
    Cardiology; 2012; 122(3):158-66. PubMed ID: 22832599
    [TBL] [Abstract][Full Text] [Related]  

  • 34. sST2 levels are associated with all-cause mortality in anticoagulated patients with atrial fibrillation.
    Vílchez JA; Pérez-Cuellar M; Marín F; Gallego P; Manzano-Fernández S; Valdés M; Vicente V; Noguera-Velasco JA; Lip GY; Ordóñez-Llanos J; Roldán V
    Eur J Clin Invest; 2015 Sep; 45(9):899-905. PubMed ID: 26081996
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Association of soluble suppression of tumorigenicity 2 with mortality and adverse outcomes in chronic kidney disease: a systematic review and meta-analysis.
    Bellos I; Marinaki S; Lagiou P; Benetou V
    Clin Exp Nephrol; 2024 Apr; ():. PubMed ID: 38678167
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Diagnosis of chronic heart failure by the soluble suppression of tumorigenicity 2 and N-terminal pro-brain natriuretic peptide.
    Jin XL; Huang N; Shang H; Zhou MC; Hong Y; Cai WZ; Huang J
    J Clin Lab Anal; 2018 Mar; 32(3):. PubMed ID: 28719009
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Association of Soluble ST2 Serum Levels With Outcomes in Pediatric Dilated Cardiomyopathy.
    You H; Jiang W; Jiao M; Wang X; Jia L; You S; Li Y; Wen H; Jiang H; Yuan H; Huang J; Qiao B; Yang Y; Jin M; Wang Y; Du J
    Can J Cardiol; 2019 Jun; 35(6):727-735. PubMed ID: 31151708
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Biomarkers for characterization of heart failure - Distinction of heart failure with preserved and reduced ejection fraction.
    Sinning C; Kempf T; Schwarzl M; Lanfermann S; Ojeda F; Schnabel RB; Zengin E; Wild PS; Lackner KJ; Munzel T; Blankenberg S; Wollert KC; Zeller T; Westermann D
    Int J Cardiol; 2017 Jan; 227():272-277. PubMed ID: 27838133
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Not Available].
    Protasov VN; Narusov OY; Skvortsov AA; Protasova DE; Kuznetsova TV; Petrukhina AA; Masenko VP; Tereshchenko SN
    Kardiologiia; 2019 Jan; 59(1S):53-64. PubMed ID: 30706839
    [TBL] [Abstract][Full Text] [Related]  

  • 40. ST2 as a novel prognostic marker in end-stage renal disease patients on hemodiafiltration.
    Homsak E; Ekart R
    Clin Chim Acta; 2018 Feb; 477():105-112. PubMed ID: 29221927
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.